Illumina Expands into Single-Cell Analysis with Fluent BioSciences Acquisition

Illumina, Inc. ILMN, a global leader in DNA sequencing and array-based technologies, announced its acquisition of Fluent BioSciences, aiming to enhance single-cell analysis capabilities and extend its market reach. This strategic move is set to provide customers with expanded access to cutting-edge single-cell analysis, an essential tool in genetic research and personalized medicine. Incorporated on April 1, 1998, Illumina has been forefront in developing comprehensive solutions for genetic analysis, with its headquarters based in San Diego, California.

Accelerating Single-Cell Analysis

The integration of Fluent BioSciences into Illumina's portfolio marks a significant advancement in the field of genetic research. Single-cell analysis allows scientists to examine the genetic make-up of individual cells, which is crucial for understanding complex biological systems and diseases. The acquisition will enable Illumina to offer more robust technology, driving innovation and discovery across a range of applications in genomics.

Expanding Customer Access and Application

Fluent BioSciences's expertise, combined with Illumina's established infrastructure, will democratize single-cell analysis by making it more accessible to researchers worldwide. The merger will potentially lead to new applications and more affordable options in this fast-growing field, supporting Illumina's mission to improve human health by unlocking the power of the genome.

Illumina, Acquisition, Genomics